Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Travere ...

Executives from Travere Therapeutics (NASDAQ:TVTX) said the company is focused on advancing treatments in three rare diseases ...

Travere Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial ...

March S&P 500 E-Mini futures (ESH26) are down -0.32%, andMarch Nasdaq 100 E-Mini futures (NQH26) are down -0.36% this morning, pointing to a lower open on Wall Street as worries about a potential ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Kiniksa Pharmaceuticals International, plc (KNSA) reports results for the quarter ended December 2025. While this ...

It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...

Comfort Systems USA, Inc. , a leading provider of mechanical and electrical contracting services including heating, ...

Cars.com Inc. , an audience-driven technology company empowering the automotive industry, today announced that it expects to ...

The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.